TECX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 7.88%, SMA50 14.67%, SMA200 18.2%). The stock’s 14-day RSI is 61.43 (firm momentum), while the ATR of 2.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.44% below its high and over 74.67% above its low. Average 10-day trading volume of 225.88 thousand shares is in line with the 3-month average of 206.31 thousand, indicating normal recent market interest.

Tectonic Therapeutic, Inc. has 18.71 million shares outstanding. The public float is 9.74 million shares, elevated short interest at 23.63% of float. This equals 2.51 million shares. The short ratio is 11.06 days. Institutional investors hold 122.27% of the float. Insiders own 39.34%. SPRINGER TIMOTHY A holds 1.50 million shares, MCGUIRE TERRANCE has 573.06 thousand shares and REICIN ALISE has 127.03 thousand shares. Over the past six months, insider transactions show net selling. They sold 15.75 thousand shares across 7 transactions.

Tectonic Therapeutic, Inc. generated EPS of -$3.85 over the past year. Five-year average earnings growth is 26.54%. Wall Street analysts project EPS growth of 8.0% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $81.00 to $64.00. The high target offers 135.88% upside. The low target suggests 86.37% downside. The mean target is $72.80. This offers 112.0% upside. Tectonic Therapeutic, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 15.52%. The prior quarter beat by -7.21%. Over the last six quarters, Apple has recorded several small beats. These include -39.57% in March 20, 2025.

Tectonic Therapeutic, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.78. This means the shares are trading above this model’s fair value.

Tectonic Therapeutic, Inc. (NASDAQ:TECX) closed at $34.34 USD, losing -$0.03 (-0.09%) from the previous close of $34.37. The stock is currently mid-range between its 52-week high and low $14.39 and $39.53. With a market capitalization of about $647.97 million, Tectonic Therapeutic, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.10). Key stats such as the average daily volume over the past year has been around 206.44 thousand shares, in line with its 52-week average. Headquartered in Watertown, MA, Tectonic Therapeutic, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alise S. Reicin, the company employs approximately 60 people and listed since June 21, 2018. Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs).

Tectonic Therapeutic, Inc. trades at a P/E ratio of -7.76, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.82 suggesting the stock is closer to book value. The P/FCF stands at -9.95, also below market averages.

Our AI price prediction model suggests that Tectonic Therapeutic, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.14%, with price expected at $38.51 by July 27, 2026, within a range of $37.33 to $39.77 3-Month Outlook: Projected fall of -28.04%, reaching $24.71 by October 09, 2026, with a range of $21.43 to $26.76. 1-Year Outlook: Projected gain of 9.78%, with price at $37.70 by July 13, 2027, within a range of $34.72 to $41.08.

Tectonic Therapeutic, Inc. (NASDAQ:TECX) shares are flat -8.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Tectonic Therapeutic, Inc. trading at a premium to the broader market with a P/E of -7.76. Analyst sentiment is cautious, with the majority of ratings in Strong Buy territory and a mean price target of $74.09, suggesting 115.75% upside. Our AI forecast model points to short-term strength (12.14% over two weeks), a medium-term fall (-28.04% over three months), and a longer-term gain (9.78% over one year), with expected trading ranges indicating moderate volatility.